Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about ...

Dr. Omar H. Llaguna, specialist in surgical oncology, programs a HistoSonics medical device for targeting a medium that ...

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

Hinge Health, which just went public last month, launched a referral network of in-person providers to complement its virtual ...

Modulating microbiome composition after allogeneic hematopoietic stem cell transplantation may help oncologists prevent bloodstream infections posttreatment.

Justin Taylor, M.D., a physician-scientist at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller ...

CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status ...

These findings are very important for patients with early-stage dMMR tumors because it’s likely they do not need surgery or radiation if they are treated first with immunotherapy for a sufficient ...

Analysts initiate coverage of Hinge Health with Buy ratings, citing strong tech, recurring revenue, and a growing $18.5 ...

Orthopedic and musculoskeletal (MSK) care leaders are facing a mounting challenge: how to grow sustainably amid flat reimbursement, workforce shortages, and increased patient demand. The answer isn’t ...

Hinge Health received widespread bullish initiation coverage on Monday from a dozen brokerages, with analysts highlighting ...